Abbott (ABT) Tops Q3 EPS by 47c, Sales Beat
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/11/2026
- S&P 500 muted as industrials counter tech drag; US-Iran peace prospects rise
- S&P 500 EPS growth above 20% is rare. Why 2027 may be at risk
- Goldman Sachs warns AI investment may be crowding out other business spending
- Why Wednesday's inflation print could provide the next dovish catalyst
- Tesla needs Robotaxi flywheel proof to boost investor conviction: Morgan Stanley
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
- After-Hours Movers: SPCX, AMD, ANET, PINS, APPS, UPST, ZETA, BKNG, LCID, CPNG, MTCH
- After-Hours Stock Movers: PLTR, SNAP, ON, ICHR, WGS, WHR
Abbott Labs (ABT) PT Raised to $145 at Jefferies
October 21, 2021 7:56 AM EDTJefferies analyst Raj Denhoy raised the price target on Abbott Labs (NYSE: ABT) to $145.00 (from $135.00) while maintaining a Buy rating following earnings.
The analyst commented, "Key post call datapoints: 1) COVID testing still elevated with $1-$1.4bn baked into 4Q guide, 2) screening versus symptomatic testing... More
